Association between treatment effect on C‐peptide preservation and <scp>HbA1c</scp> in meta‐analysis of glutamic acid decarboxylase (GAD)‐alum immunotherapy in recent‐onset type 1 diabetes-Reference-Cited by-同舟云学术

Association between treatment effect on C‐peptide preservation and HbA1c in meta‐analysis of glutamic acid decarboxylase (GAD)‐alum immunotherapy in recent‐onset type 1 diabetes

Published:2022-05-26 Issue:8 Volume:24 Page:1647-1655
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Nowak Christoph¹²^ORCID,Hannelius Ulf²,Ludvigsson Johnny³^ORCID

Affiliation:

1. Karolinska Institutet, Department of Neurobiology Care Sciences and Society Huddinge Sweden

2. Diamyd Medical AB Stockholm Sweden

3. Crown Princess Victoria Children's Hospital and Division of Pediatrics, Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden

Funder

Barndiabetesfonden

Diabetesfonden

Western Michigan University

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14720

Reference12 articles.

1. β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial

2. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function

3. Effect of Intensive Therapy on Residual β-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications Trial

4. Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial

5. Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers;BMC Medicine;2024-06-21

2. First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes;BMC Medicine;2023-05-24